LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4455 | 5578 | 0.7986 | 0.6298 |
| SK-BR-3 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2296 | 5578 | 0.4116 | -0.0814 |
| SK-BR-3 | LDN-193189 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5820 | 5578 | 1.0433 | 1.0795 |
| SK-BR-3 | Linifanib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5556 | 5578 | 0.9960 | 0.9926 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4923 | 5578 | 0.8825 | 0.7840 |
| SK-BR-3 | Mitoxantrone | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1877 | 5578 | 0.3365 | -0.2196 |
| SK-BR-3 | Mitoxantrone | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1527 | 5578 | 0.2738 | -0.3347 |
| SK-BR-3 | MK2206 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4103 | 5578 | 0.7355 | 0.5138 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1569 | 5578 | 0.2814 | -0.3208 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 6233 | 5578 | 1.1173 | 1.2156 |
| SK-BR-3 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5471 | 5578 | 0.9807 | 0.9645 |
| SK-BR-3 | NU7441 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5567 | 5578 | 0.9980 | 0.9964 |
| SK-BR-3 | Dactolisib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 2331 | 5578 | 0.4180 | -0.0698 |
| SK-BR-3 | NVP-TAE684 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4515 | 5578 | 0.8094 | 0.6497 |
| SK-BR-3 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4466 | 5578 | 0.8006 | 0.6334 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5248 | 5578 | 0.9408 | 0.8912 |
| SK-BR-3 | PD0325901 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5325 | 5578 | 0.9545 | 0.9164 |
| SK-BR-3 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5623 | 5578 | 1.0079 | 1.0146 |
| SK-BR-3 | PD184352 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5922 | 5578 | 1.0616 | 1.1132 |
| SK-BR-3 | Pelitinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4239 | 5578 | 0.7599 | 0.5587 |
| SK-BR-3 | PF431396 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4706 | 5578 | 0.8436 | 0.7126 |
| SK-BR-3 | PF477736 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1652 | 5578 | 0.2962 | -0.2936 |
| SK-BR-3 | PF562271 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5530 | 5578 | 0.9914 | 0.9842 |
| SK-BR-3 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5839 | 5578 | 1.0467 | 1.0858 |
| SK-BR-3 | PHA-793887 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2647 | 5578 | 0.4745 | 0.0341 |